The Problem: When Standard Cancer Treatment Stops Working

Roughly 30–40% of patients with diffuse large B-cell lymphoma either do not respond to first-line chemoimmunotherapy or relapse after it. For those patients, the next step used to be salvage chemotherapy followed by stem cell transplant — if they were eligible. Many are not. Older patients, those with comorbidities, or those whose disease progresses too quickly never make it to transplant.

That is the population CAR-T was built for. The pivotal ZUMA-1 trial, published in the New England Journal of Medicine, showed a 54% complete response rate in patients with refractory DLBCL treated with axicabtagene ciloleucel. Five-year follow-up data demonstrated that roughly one-third of those patients remained in remission without additional therapy. Those are patients who had failed multiple prior lines of treatment.

But the price. In the United States, the list price for a single CAR-T infusion ranges from $373,000 for brexucabtagene autoleucel to $475,000 for axicabtagene ciloleucel, excluding hospital costs, which can add another $50,000–$100,000. Insurance coverage is inconsistent. Even with approval, many patients face months of appeals, and some are denied outright. In Europe, access is similarly uneven. The UK’s NHS has negotiated discounts but still restricts eligibility tightly. Canada and Australia have approved CAR-T but treat limited numbers of patients annually.

So patients look elsewhere. And increasingly, they look at China.

Why China Has Become a Serious CAR-T Destination

Clinical Trial Volume Means Real-World Experience

China leads the world in CAR-T clinical trial registrations. A 2023 analysis in Nature Reviews Clinical Oncology found that China accounted for more than 50% of all registered CAR-T trials globally. More than 500 CAR-T trials have been initiated in China since 2016. That is not just a number — it means Chinese hematology departments have managed cytokine release syndrome, neurotoxicity, and long-term follow-up in thousands of patients.

Six CAR-T products have received approval from China’s National Medical Products Administration (NMPA). These include Yescarta (axicabtagene ciloleucel), approved in 2021, and Carteyva (relmacabtagene autoleucel), a domestic product approved for relapsed or refractory large B-cell lymphoma. Several other Chinese-developed CAR-T products target BCMA for multiple myeloma.

Cost Structure: Why CAR-T Therapy Cost China Is Lower

The most direct answer to the question of CAR-T therapy cost China is this: commercial CAR-T products in China are priced at roughly 1.2 million RMB per treatment. At current exchange rates, that is approximately $100,000–$150,000, depending on the specific product and hospital fees. That is one-third to one-quarter of the US price.

Why the difference? Not because the therapy is inferior. The manufacturing process is the same — viral vector transduction, cell expansion, quality control. The cost difference reflects structural economics: lower labor costs for hospital staff and manufacturing technicians, lower facility overhead, and a domestic supply chain for many reagents. Chinese regulators also negotiated pricing with manufacturers as a condition of market approval. The result is a genuinely lower price without a different clinical product.

Hospital fees, pre-treatment lymphodepletion chemotherapy, and management of side effects add to the total. In China, those ancillary costs typically run an additional $15,000–$30,000. In the US, they can double the final bill. That is a meaningful difference for families paying out of pocket.

Hospital Infrastructure Built for Cell Therapy

China’s top hematology departments are not small operations. Hospitals like Ruijin Hospital in Shanghai, Peking University People’s Hospital in Beijing, and the First Affiliated Hospital of Zhejiang University in Hangzhou run large bone marrow transplant and cell therapy programs. Ruijin’s hematology department, for example, manages more than 1,000 inpatient beds across its network and has been a primary clinical site for multiple CAR-T trials. The volume of patients means the nursing teams, ICU staff, and laboratory technicians have seen the complications. They know what cytokine release syndrome looks like at 2 a.m. That matters.

Our database of top-ranked Chinese hospitals includes hematology departments with active CAR-T programs, all ranked among the top tier by the Fudan University hospital rankings.

How Does CAR-T Therapy Work for Lymphoma: The Actual Process

If you are asking how does CAR-T therapy work for lymphoma, the short version is this: it turns your own immune system into a targeted weapon. The longer version involves several distinct steps, each with its own timeline and risks.

First, leukapheresis. Blood is drawn through a catheter, and a machine separates out T cells while returning the rest of the blood to your body. This takes three to four hours. The collected T cells are frozen and shipped to a manufacturing facility, where they are genetically modified with a viral vector to express a chimeric antigen receptor — a synthetic protein that recognizes a specific marker on lymphoma cells, most commonly CD19.

Manufacturing takes two to four weeks. During that window, most patients receive bridging chemotherapy to keep the lymphoma under control. Once the engineered cells are ready, you undergo lymphodepleting chemotherapy — typically fludarabine and cyclophosphamide — for three days. This suppresses your existing immune system so the infused CAR-T cells have room to expand.

Then the infusion itself. It takes about 30 minutes. The real work happens over the following two to four weeks, when the CAR-T cells multiply inside your body and begin attacking lymphoma cells. This is also when the two most serious side effects can appear: cytokine release syndrome (CRS), an inflammatory response that can cause fever, low blood pressure, and in severe cases organ dysfunction, and immune effector cell-associated neurotoxicity syndrome (ICANS), which can cause confusion, seizures, or cerebral edema. Both are manageable in experienced centers. Both can be fatal in inexperienced ones.

You stay near the hospital for at least four weeks after infusion. Most centers require daily monitoring for the first two weeks. Full recovery of the immune system takes months.

Is CAR-T Therapy Available for International Patients in China? What to Know

The short answer is yes. Is CAR-T therapy available for international patients in China? It is — but not through the ordinary outpatient route. Chinese public hospitals do not allow overseas patients to book outpatient appointments remotely. You cannot email a hospital and reserve a CAR-T slot. The standard path for a foreign patient starts with a remote evaluation through the hospital’s international department or a coordination service.

That evaluation requires your complete medical records: pathology reports, PET-CT scans, prior chemotherapy regimens, and a current physician’s summary. The Chinese hematology team reviews these and determines whether you are a candidate for CAR-T at all. Not everyone is. CAR-T is approved in China for specific indications: relapsed or refractory DLBCL after at least two lines of systemic therapy, relapsed or refractory ALL in certain patient groups, and relapsed or refractory multiple myeloma for BCMA-targeted products. If your disease does not fit those labels, the answer will be no.

Once the team confirms eligibility, you travel to China for an in-person consultation. The hospital will repeat some diagnostics. Only after that face-to-face assessment does the treatment plan get finalized and a slot get scheduled. This is the same rule for Chinese citizens — no surgery or cell therapy without an in-person visit first.

Best CAR-T Hospitals in China: Where the Experience Concentrates

If you are researching the best CAR-T hospitals in China, you will find the strongest programs concentrated in three cities: Shanghai, Beijing, and Hangzhou. These are not the only options, but they account for the majority of commercial CAR-T infusions and clinical trial sites.

Ruijin Hospital in Shanghai, affiliated with Shanghai Jiao Tong University School of Medicine, has been the lead site for several pivotal Chinese CAR-T trials and has treated hundreds of commercial patients. Its hematology program is consistently ranked among China’s top three by the Fudan University specialty rankings. CAR-T treatment price Shanghai at Ruijin’s international department typically falls within the $100,000–$150,000 range, with additional hospital fees depending on length of stay and complication management.

In Beijing, Peking University People’s Hospital runs one of the largest allogeneic transplant and cell therapy programs in Asia. Its hematology institute has deep experience with CRS management and long-term follow-up. The First Affiliated Hospital of Zhejiang University in Hangzhou is another major CAR-T center, particularly for BCMA-directed products in multiple myeloma.

Our department rankings by specialty include hematology lists that show which hospitals rank in China’s top 10, based on the Fudan specialty reputation rankings. For a broader view of the cities where these hospitals are located, see our guides to medical treatment in Shanghai and hospitals in Beijing.

Practical Considerations: Visas, Payment, and Follow-Up After CAR-T in China

You will need an S2 visa for medical treatment in China. The S2 visa covers short-term private affairs, including medical treatment, and is the correct category for a patient traveling for CAR-T evaluation and therapy. Your accompanying family members apply for the same visa type. The hospital’s international department will provide an invitation letter and treatment confirmation, which you submit with your visa application. Processing times vary by embassy, but plan for at least two to four weeks.

Payment is upfront. Chinese public hospitals require a deposit before treatment begins, and the full balance is typically due before discharge. The international department will give you an itemized cost estimate after the in-person consultation. Most accept international credit cards or wire transfer. Private international hospitals in China, such as those listed in our private hospital directory, may accept direct insurance billing, but public hospital international departments generally do not. You pay, then seek reimbursement from your insurer.

Language is a real barrier. Public hospital staff outside the international department rarely speak English. The international department provides some interpretation, but for daily interactions — pharmacy, radiology, lab draws — you will need help. This is where a bilingual medical companion becomes practical, not optional. The cost for such a service in China starts around $300 per day.

Follow-up after returning home is essential. CAR-T requires monitoring at 30 days, 90 days, 6 months, and 12 months post-infusion, including PET-CT scans and blood work. Your Chinese medical team will provide a written follow-up protocol. You can complete these scans in your home country and send results back for review. Some patients return to China for the 90-day and 6-month assessments. The logistics are manageable, but they require planning.

Frequently Asked Questions